Artificial Intelligence Methods Available for Cancer Research
Overview
Authors
Affiliations
Cancer is a heterogeneous and multifaceted disease with a significant global footprint. Despite substantial technological advancements for battling cancer, early diagnosis and selection of effective treatment remains a challenge. With the convenience of large-scale datasets including multiple levels of data, new bioinformatic tools are needed to transform this wealth of information into clinically useful decision-support tools. In this field, artificial intelligence (AI) technologies with their highly diverse applications are rapidly gaining ground. Machine learning methods, such as Bayesian networks, support vector machines, decision trees, random forests, gradient boosting, and K-nearest neighbors, including neural network models like deep learning, have proven valuable in predictive, prognostic, and diagnostic studies. Researchers have recently employed large language models to tackle new dimensions of problems. However, leveraging the opportunity to utilize AI in clinical settings will require surpassing significant obstacles-a major issue is the lack of use of the available reporting guidelines obstructing the reproducibility of published studies. In this review, we discuss the applications of AI methods and explore their benefits and limitations. We summarize the available guidelines for AI in healthcare and highlight the potential role and impact of AI models on future directions in cancer research.
Ocana A, Pandiella A, Privat C, Bravo I, Luengo-Oroz M, Amir E Biomark Res. 2025; 13(1):45.
PMID: 40087789 DOI: 10.1186/s40364-025-00758-2.
Deep Learning Models for Predicting the Recurrence of Idiopathic Granulomatous Mastitis.
Li L, Yang W, Jia H J Inflamm Res. 2025; 18:2943-2953.
PMID: 40026307 PMC: 11872085. DOI: 10.2147/JIR.S499512.
Shen D, Sha L, Yang L, Gu X BMC Infect Dis. 2025; 25(1):151.
PMID: 39891059 PMC: 11786570. DOI: 10.1186/s12879-025-10566-6.
Large language models in cancer: potentials, risks, and safeguards.
Zitu M, Le T, Duong T, Haddadan S, Garcia M, Amorrortu R BJR Artif Intell. 2025; 2(1):ubae019.
PMID: 39777117 PMC: 11703354. DOI: 10.1093/bjrai/ubae019.